Related Experiment Videos
[Hypercalcemia: a finding indicative of a prostatic adenocarcinoma]
Actas Urologicas Espanolas
|September 1, 1989
Summary
Hypercalcemia is a rare complication of prostate cancer, sometimes indicating recurrence or preceding diagnosis. Hormone therapy effectively normalized calcium levels in a patient with prostate carcinoma presenting with hypercalcemic syndrome.
Area of Science:
- Oncology
- Endocrinology
Background:
- Calcemic alterations, particularly hypercalcemia, are uncommon in prostate cancer.
- Hypercalcemia can manifest with osseous dissemination or via humoral mechanisms.
- It may signal tumor recurrence or precede the initial diagnosis.
Observation:
- A 76-year-old male patient was diagnosed with prostate carcinoma.
- The diagnosis was prompted by the presentation of a hypercalcemic metabolic syndrome.
- This syndrome is a rare clinical manifestation of prostate cancer.
Findings:
- The patient's hypercalcemic metabolic syndrome was successfully treated.
- Normalization of blood calcium levels was achieved through complete androgenic blocking (hormone therapy).
- Hormone therapy is effective in managing hypercalcemia in disseminated prostate adenocarcinoma.
Implications:
- Hypercalcemia can be an early indicator of prostate cancer, even before overt symptoms.
- Complete androgenic blocking is a viable treatment strategy for managing hypercalcemia associated with prostate cancer.
- This case highlights the importance of investigating calcemic alterations in the context of prostate cancer diagnosis and management.